Transcript 0:00 Hey, folks, it's Quinn. Since we recorded this conversation, we've renamed the podcast. It used to be called Important Not Important, which is what you'll hear in the episode and is still the name of the company. 0:12 But now the podcast is called The Most Important Question. That is, what can I do? 0:18 It's the question we get the most from all of you, and it turns out it's the question I've really been asking guests for almost two hundred episodes now. So here we are, The Most Important Question. 0:29 Please enjoy this old conversation. Thanks for listening, and thanks for giving a shit. [upbeat music] Welcome to Important Not Important. My name is Quinn Emmett, and this is science for people who give a shit. 0:46 Folks, I have spent the last two years trying to understand and focus in on what we do best here, and it's increasingly clear that that is answering the question: What can I do about climate? 1:02 What can I do about COVID or cancer or hunger, clean water, maternal health, air pollution, or some other make-or-break issue? 1:11 We tell you what's happening, who's involved, how to think about it, and what the hell you can do about it. I want to tell you a couple quick stories. 1:20 Fourteen years ago, my beloved cousin was suddenly diagnosed with cancer. We share a birthday. I love her. She was so young, and I didn't know how to help, right? I wasn't a doctor, wasn't a scientist. 1:36 I mean, clearly, I'm still not [chuckles] either of those, but I wasn't anything that could directly help her. Someone told me about Team in Training, which is the fundraising arm of the Leukemia & Lymphoma Society. 1:49 Now, they bring supporters together to train and run marathons and triathlons and raise money to fight blood cancers. And I realized this, running and sweating, this is-- I can do this, right? I can sweat. 2:05 I can raise a ton of cash. I can donate it all to the doctors and researchers who actually know what the hell they're doing. I was elated, right? I have a part to play. 2:15 I can play my part, and that's important because I can use this thing I know how to do for good. I can help myself feel better on one hand, but maybe also contribute to fixing the larger problem itself. 2:30 My cousin survived. She's flourishing. She's getting married. So when one of my best friends got cancer a couple years ago, I did the same thing. 2:39 I ran, and I ran, and I ran, and I raised a truckload of money for research and for his treatments because I felt equally desperate but a little more empowered. My friend's name was Andy, and Andy didn't make it, 2:54 but I think I'm here today doing this because of him. This feeling, needing, but also being able to do something to help, to also feel better, it-- the whole thing just stuck with me. 3:11 And now we're here today, and you're here today trapped with me. I'm here today. I've got this whole thing, right, where I've realized the best answer to the question, "What can I do?" is what can you do? 3:25 There's so many things you can do because there's so many of you, and you've each got these wonderful talents and passions, and there's so much to do, right? 3:35 While climate and COVID are these global issues that touch everyone and everything, there's a million other situations and moments that challenge each of us in unique ways that can make us feel 3:50 helpless, sometimes even alone. A loved one facing a rare disease is among those, and among the scariest, because we are very often not the person best suited to directly help that person, if anyone can help at all. 4:05 Jafar Tabebordbar was in his early thirties, living and working as an accountant in Shiraz, Iran, when he became a father. 4:15 It was nineteen eighty-six, nearly a decade after the nineteen seventy-nine revolution, and Jafar's muscles were already beginning to wither. 4:23 As his sons grew and watched, their father, Jafar, lost his balance, his ability to walk, to drive, and eventually the reliable use of his hands. 4:34 There were no answers, no treatments to be found, so two questions haunted his sons as they grew. What was causing their father's suffering? Would they get it next? My guest today, thirty years later, is Dr. 4:49 Sharif Tabebordbar, Jafar's oldest son and the man closest to a cure. 4:56 Sharif received his bachelor's and master's degrees in biotechnology from the University of Tehran and a PhD in developmental and regenerative biology from Harvard University. 5:06 He is the recipient of Distinction in Teaching Award from Derek Bok Center for Teaching and Learning at Harvard, from the Albert J. 5:13 Ryan Foundation for Outstanding Graduate Students in Biomedical Sciences, of the Excellence in Research Award, and the Career Development Award from the American Society of Gene and Cell Therapy, and the Royan International Research Award in Regenerative Medicine. 5:28 In two thousand and twenty, Sharif was listed as a finalist in the MIT 35 Innovators Under 35 competition. 5:35 In two thousand and twenty-one, Sharif and others posted an article in the journal Cell that may change the world. All of these years later, thousands of miles away, Jafar's son Sharif has figured out how to help. 5:50 He stands on the cusp of transforming gene therapy for nearly all muscle-wasting diseases. [gentle music]Dr. Tabatabordbar, welcome. Thank you. Of course. Thank you so much for coming on the show today. 6:06 So excited to share your story and your work with the folks out there. And again, like we talked a little bit about offline, because of everything that's going on, this is what happens, right? 6:16 With climate and COVID and things like that, we often forget about all of the other things that are happening on a day-to-day basis in science and in the world, regardless, whether that's work like yours or just getting clean water to folks or getting food to folks, that it's so important to really focus on stories like yours because there's a lot of folks who are coming to us. 6:35 That's why we call it science for people who give a shit, who are touched by science in some way. I mean, we've all been trapped in our living rooms for the past two years because of it. 6:42 So [chuckles] if you didn't think it was gonna find you, here we are. And there's people who are going like, "What can I do? What can I do?" 6:47 And I, I feel like your story is, is so beautiful and practical and pragmatic, but also a difficult one. I'm excited to get into that. No, I appreciate it so much, and I'm really happy to be on your podcast. 6:58 You say that now. Give it, give it some time. [laughs] You can join our other hundred and thirty guests with all their regrets. 7:04 [laughs] Sharif, we do like to start with one important question 'cause I like for the show to be informative and compelling and dramatic and actionable, but also have a little levity here and there. 7:15 So one question we ask to set the tone, we like to ask, Sharif, why are you vital to the survival of the species? And I encourage you to be bold and honest because you are here for a reason. That is a very bold question. 7:29 Uh, why am I essential to the survival of the species? I think the work that I'm doing is gonna help certain individuals who are born with genetic diseases that they had no control over live a better life. 7:45 I think my work is vital to equity and to give people more equal opportunities to live their life. 7:52 I think the species will survive without me, but probably there, there would be more people who live a better quality of life. I think that's pretty wonderful. I joke, you know. 8:02 [laughs] I try to empower my children, who are very privileged and, and relatively healthy. You know, when they say, "Well, what are you doing at work today?" I'm like, "I've got a podcast." 8:10 Meanwhile, there's folks like you out there, as we like to say, on the front lines of the future, just working on these truly miraculous things. 8:16 So, so thank you for that, and thank you for answering my ridiculous question. So Sharif, I actually usually save this particular question for the end, but it actually in your case, 8:28 seems better to just start at the beginning, considering your work and your family. 8:34 When was the first time in your life when you realized you actually had the power of change or the power to do something meaningful to help in some way? I think there were 8:47 a few people who really had a major experience in the path that I chose for my life. I would like to give shout-out to them whenever I get a chance. 8:57 I think one of those people was a very good friend of mine, uh, Eric Wang, who has family members affected by a certain form of genetic muscle disease, and I saw his story. 9:12 I saw that basically he devoted his life and career into studying that disease and trying to find treatments for that. 9:20 And when I saw him, it was always in the back of my mind that I need to do something about this, but I didn't know where exactly to start to have the most meaningful impact. 9:32 And watching Eric's story, watching how he actually found all the right people, put a team together, tried to basically move toward that goal with surrounding himself by, like, really wonderful people inspired me. 9:47 Mm-hmm. And it gave me the motivation that I want to do the same thing. 9:52 I want to find the right people who's, who are gonna help me, who are gonna be part of this journey, and then I'm gonna try as hard as I can to make this happen. 10:01 So I think meeting Eric Wang was one of the highlights of my journey. So how old were you, if you could frame that for us, when you encountered Dr. 10:11 Wang and, and had this sort of moment where you realized, "Oh, I could build something like this"? I think I was twenty-two years old. Okay. 10:21 But again, like, since I was a, like, high school student, it was always in the back of my mind that I need to do something- Mm. 10:31 -to help people who are born with genetic diseases because in my mind, the fact that you're born with some mutations in your DNA that you absolutely have no control over is very unfair. 10:47 Like, life is unfair in general, right? Sure. 10:49 There are things that you can change, and there are things that you can't, but this one was a very true example of you're born with something you have no control over, and this is, like, completely unfair. 11:00 There has gotta be a way to change this. There has gotta be a way to help people who are born this way, and that was always my motivation. 11:08 That was always the reason that I chose my majors in school when I went to college and then grad school. But, uh, meeting Eric was, like, the defining moment that, okay, I can actually do something meaningful about this. 11:22 Like, I can, I can study. I can, like, do research, but how can you make an impact? How can you make a change that actually is gonna change people's lives? Sure. 11:30 I appreciate that from obviously surface level, obviously, but a thousand other ways. I mean, everyone here knows, like, I look like this. 11:38 I was, I was born healthy, you know, in America in the, in the late twentieth [chuckles] century, and that's about as lucky as it gets. As my dad calls it, it's the lucky sperm club. 11:47 I've never wanted or needed for food or water. 11:50 I don't have any particular, uh, genetic issues, but along this journey of the work I do here, I've come to realize more and more every day, and I try to build a show and, and a series of conversations that are more inclusive of lived experiences that are, that are different than mine so that I canTry to truly understand these things. 12:08 We see it every day, right? 12:09 Which is start in America, or you can look at New Delhi, like, the, the people who deal with the air pollution, that it's not a genetic disease per se, but it is something that they did not ask for, right? 12:20 Or water quality or whatever it might have been. But genetic disease is so specific because we've only really come to understand it very recently. 12:29 So I wonder at what point in your youth before meeting Eric, high school, whenever it might have been earlier than that, as you watched your dad suffer, when did you, I guess, realize that this was something that he didn't ask for? 12:45 That there wasn't some chemical thing. He wasn't a smoker. You know, it wasn't a car accident. It wasn't any of these things that you realized, oh, this is sort of the ultimate unfairness. 12:55 Um, not only did he not do anything to, to instigate it, but we don't know what it is or why it is. It was when I was a teenager. I mean, my dad lived a healthy lifestyle. He was not a smoker. He was... 13:05 Like, it was not his lifestyle that was causing the issue. And the condition that he has was a very progressive condition. So I do remember when I was very young, he would walk okay. 13:15 He limped a little bit, but he got around. 13:17 I even remember him riding a bike, and then over time it was declining, and he couldn't ride a bike, and then he couldn't, like, take a walk with us in the park anymore because he was very afraid that he's gonna fall. 13:31 At some point he stopped driving. It wasn't safe anymore, and eventually he got wheelchair-bound. 13:36 I think the time that I realized there's something going on and it's genetic is, it was when I was, uh, when I was a teenager, maybe I was like 14 or 15 years old. 13:46 When you're young, it's a hard thing to wrap your head around, right? 13:48 Because like you said, there, there's an immense amount of injustice in this world, and we're realizing that and, and in many ways we've, we've worked to alleviate that, but we still have a long way to go, right? 13:57 We've made huge strides against poverty and childhood diseases, but there's still so many who, who suffer from them. 14:03 But I think about my six-year-old who's constantly, uh, complaining that something is unfair because he's the third child and [laughs] gets the short thrift, and I have to remind him that the complaint something is unfair does not apply to him in, in sort of the, the global sense. 14:17 But there is this, this sense of looking around and going like, "How could this be? Why him? Why does this have to happen if his lifestyle is not contributing this into some way?" 14:25 You said you had that feeling when you were 14 and 15. Now, from what I understand, you then had to compete for a spot at the University of Tehran. Is that correct? Right. And what were the odds of actually getting in? 14:38 [laughs] So yeah, the way the university entrance exam in Iran works is that every single high school student in the country needs to take part in this four or five hours exam- Okay... in one day at one specific time. 14:54 And basically you choose the major of your career based on the results from that exam. 14:59 So it's, it's very high stakes and a lot of people spend, like, more than a year of their life to, like, just study for that one exam. 15:06 So I, I did spend about, like, a year and a half basically not doing anything else other than studying for this one four-hour exam, and it was extremely stressful. I was, I think, 17 years, 18 years old at that time. 15:18 There was this one program that I was really passionate about. 15:20 It was called the biotechnology program at University of Tehran, and it had everything that I really loved about biology and genetics and genetic engineering. Mm-hmm. 15:31 It give you a very interdisciplinary view of different sciences, prepared- Mm-hmm... you for getting into biomedical science, but it was extremely competitive. 15:40 I think they, they accepted about 10 students each year, and a few of those students were actually from... Like, we have also this other competition named Olympiads for- Mm-hmm... 15:52 like, different sciences, and then- Mm-hmm... folks who get a gold medal in the Olympiads, they don't need to take part in this university entrance exam. Okay. 16:00 So a few of the spots already gets filled with people who get gold medals from Olympiads. [laughs] So it's not really 10. It's actually, like, five or six. It's five or six. Yeah. 16:09 And out of how many kids, at least when you were growing up, were taking this exam on this one day at this one specific time across Iran? It depends. Year to year it's different. 16:17 When I looked up the specific year that I took the exam, I think it was 1.2 million people, uh, that took that exam, so it's, it's a very large community- Mm-hmm... that's competing against each other. 16:27 And you actually rank, get ranked [laughs] from number one to, like, whatever number. [laughs] Oh, no. [laughs] So it's, yeah, it's pretty intense. Oh, geez. [laughs] I ranked seventh in that exam on that year. 16:39 I was lucky enough to get into that program. That was, that was something that I really worked hard for. Yeah, fortunately that panned out. I mean, you say you were lucky enough to get in. 16:48 Obviously that, that set up so much of the rest of your life and where you are today, but you also said you [laughs] worked for a year and a half doing basically nothing else on that. 16:56 What do you feel like set you apart in that moment besides just hard work from 1.293 [laughs] million- Yeah... other kids of the same age on the same day? Like, what gets you there? What put you over the top? 17:11 I think it's motivation. It's actually wanting to do something really bad, like persistence, not letting failure stop you. There have been moments during that year and a half that, you know, I had bad days. 17:27 I, I took a lot of practice exams, and there were days that I didn't do well, but you get down, you get bumped then when you don't get the results that you expect, but then I think coming up and having the mindset that, "Okay, what can I learn from this failure? 17:44 How can I do better next time? What went wrong that I had this bad experience?" And it took a while for me to come to that stage that I could actually take it. I could not collapse when something goes wrong. 17:58 But over time, I learned that I would prepare myself for the worst, but then when a good outcome happens, I'm gonna be really happy. I'm gonna do my best. 18:08 I'm gonna do anything in my capacity to make sure that I do well.But then there is a very good chance that it doesn't go well. And it's okay Mm-hmm. It's fine. 18:16 It, it happens, and you just gotta take a step back at that point, take a look at what happened, learn from it, and do better next time. 18:24 So I think, uh, perseverance and really wanting to do something is really important. It's like you obviously work hard, you have to also try to learn from your mistakes and get better over time. 18:36 I think that's maybe something that helped me. [chuckles] I mean, it seems like it's two things. 18:40 You had such a specific intimate motivation, clearly, at home to set yourself up for, for success so that you could work on something related to this, to go on to meet Eric- Mm-hmm... 18:52 to build a team, to work with a team. But I imagine that... Were there practice tests along the way? Like, h-how did those go? 18:59 Were you seeing indicators that you would be successful [chuckles] or, or was it like, "Oh, shit, I've gotta work harder"? I did. So that's the other thing. 19:06 I think the other thing that really helped me out was peer pressure. So I went to a school 19:13 that was part of a system that was called NODET, or National Organization for Development of Exceptional Talents, and that's a system- Okay... 19:21 that we have in Iran that's also, like, an entrance exam for high school students, I think, like elementary and high school students to get into that system. Mm-hmm. 19:29 And once you get in, then you're surrounded by people who are competitive and intense, and they want to succeed. So there was a lot of peer pressure. I do remember [chuckles] 19:40 that year, the class that we had was 17 people, and there were three of us who were fiercely competing with each other. 19:47 There was this one guy, his name was Sayid Khaishi, and he's now a, I think, an eye surgeon back in Iran. He ranked first in the whole country almost in every single practice exam that he took. Oh my God. 20:01 Oh, wait, they ranked the practiced ones, too? Yeah, yeah. Oh. You get, you get ranked on, like, all these exams. It's, it's pretty intense. [laughs] Oh, so, so- Very stressful times. [laughs] And then, 20:13 uh, I usually ranked second. Like, there were a couple instances that it got flipped, but it was this, like- Okay... extremely fierce [chuckles] competition between me and Sayid. Oh my God. 20:24 [chuckles] And that really helped me. That pushed me to the edge. Sure. I was like, "I really want to be the first one right now," [chuckles] "so how can I make that happen?" 20:31 But surrounding yourself with people who, who are competitive and intense can help, you know, as long as it's a- Sure... healthy competition. 20:39 [chuckles] It can be a fine line, certainly, at that age and, and when, when the spots are so few and they're like, "It's 10," and it's actually four to five. 20:47 Oh my God, uh, the fact that the, the practice tests were ranked and, and shared along the way, I mean, I definitely would've been somewhere in the six digits and just been like- [laughs]... "Well, that's it." 20:56 [laughs] "Guess I'm, guess I'm a baker." [laughs] And baking's great, but, uh, are we helping people? That's, that's incredible. Wow. 21:03 So it seems like, though, that your practice and your success there and, and your trials and tribulations, I feel like there's this whole thing in the past couple years, right, of trust the science, follow the science, and that's impeccable. 21:14 But there's a... I'm not sure if you've ever seen the movie The Princess Bride, but there's this, uh, quote that says, like, "I do not think that word means what you think it means." And it's the idea of, like, 21:25 w-we have to remind people what science is, right? It's not this ultimatum or, or a threshold that you cross, right? It's a process where... 21:32 And I imagine with the work that came before you in your field and that you're doing now, even with your, your recent advancements, that I have to imagine, and please correct me if I'm wrong, that you expect failure most of the time. 21:43 I mean, you're going out to prove yourself wrong over and over and over and over. Is that... Do I have that wrong? That's usually how it works in preclinical studies. 21:50 So when you do rodent studies or, like, earlier studies. When you get to the point that you get into human clinical trials, there are a lot of... The regulation is much harder, right? 22:00 They don't allow you to obviously go into human clinical trials if you don't have the right safety margins, for good reasons, obviously. 22:08 So when you get to the human clinical trial stage, it's de-risk to a certain stage, but there is always risk involved. So yes, to some extent you have to always prepare for the worst, but be as prepared as possible. 22:21 I think about, you know, these mRNA vaccines that, that are incredible and, and everyone's like, "Oh, they're great. They're really great." And it's like we gotta put these things in context. 22:28 I mean, the decades of work that went into them and vaccines along the way and the research- Yeah... 22:32 it's like the human clinical trials of, of anything are the metaphor, the tip of the iceberg, and the rest of the iceberg's just, just decades of failure and, and learning and processes- Yeah... along the way. 22:43 Imagine you didn't just show up on the scene after finishing in the top 10 and just be like, "I've got the answer." No. [chuckles] No. Takes a very long time. I always describe to folks, I endeavor... 22:55 I'm a liberal arts major, which in the US is feelings and emotions and ethics and things like that, so flashcards were not my jam. Like I said, I would've finished in a, in a not great place in, [chuckles] in your exam. 23:06 But I do really try in sort of this broader generalistic sense to synthesize all of these different things, but also out of respect, but also so it's more of a conversation than an interview to try to get what in the US we call a, quote-unquote, "301," which is, you know, not a 401, n-not a 101, in each of these conversations ahead of time. 23:25 I tried really hard to understand the technical description of your work, and I am floating in the ether around it. So- Okay... 23:35 I think I figured out a sort of an analogy, but I wonder if for the people, if you could describe to us in technical terms what it is that you're working on, and then I will try to, I don't wanna say dumb it down, but make it something that people like me can try to understand at least the implications of- Okay... 23:52 and where we are. Go for it. No, I can definitely try. 23:56 When folks have specific changes in their DNA, in basically the genetic material that codes for the proteins that make your body, then there would be some specific protein that-Go missing or they cannot perform the function that they usually perform. 24:19 So that's when they call it a mutation. There is a change in the DNA that basically results in some sort of defect in the body. 24:28 And sequencing the human genome, which happened nearly two decades ago, helped to understand what are the cause of each different genetic diseases, right? 24:40 What are the genes that are mutated, that are changed, that cause the diseases that we see in the human population? 24:48 Huntington's disease, cystic fibrosis, Duchenne muscular dystrophy, Tay-Sachs disease, spinal muscular atrophy. 24:55 And a lot of these diseases are actually caused by changes in one specific gene, in one specific piece of DNA. Out of how many pieces? I think it's more than 30,000 genes, like protein-coding genes in the, in the body. 25:11 Okay. And they have shown, like research in the last 25, 30 years have shown that if you compensate and restore 25:24 the healthy copy of that gene, right, the, the, the version of the gene that's not mutated to the cells, to the body, you can actually definitely 25:35 inhibit the progression of the disease and in some cases even reverse the symptoms. So the earlier that you intervene is going to be better obviously, because there is less damage to the body. 25:45 So the question is now, okay, now you know what gene is mutated, you know what gene is broken, you know that if you put it back, it's gonna fix it. How do you actually do it? 25:56 Like, how do you put this gene back into the body? To be clear, folks, he's not asking me the answer to the question. That's not how this goes. [laughs] This is a rhetorical question. 26:07 [laughs] No, I'm just kind of trying to elaborate [laughs] in a, in a non-technical term. Don't worry, he's got it. [laughs] No worries. 26:14 [laughs] And the best way that scientists have found to do this is actually to use viruses, but a specific type of viruses, viruses that are not pathogenic. So 26:30 specifically after the pandemic, whenever we hear the word virus, everybody's like, "Ooh, like something bad- Right... is gonna happen." But there are actually a lot of viruses that we on- encounter on a daily basis. 26:42 We get infected with, but we never know because they're not associated with disease. They are... They're endemic in the h- human population. 26:49 We all have seen it at some point in our life, uh, but they're not causing disease. That's why we don't really know about them. One of those viruses is called adeno-associated viruses, or AAV. Okay. 27:02 And it's an extremely small virus that can get into the bloodstream, can get into different tissues in the body, mainly it goes to liver. 27:11 And but we usually don't know about it because, again, we don't get sick unless you have like some sort of adenovirus or herpes infection. It could potentially be a very exciting tool, right? 27:21 Because it has the capability to get into human tissues. It's not causing disease. How can we use this- Mm-hmm... for delivering these genes or for basically doing gene therapy? Mm-hmm. 27:34 And the way researchers have developed this tool is that they have taken out the endogenous genes for the virus, so basically whatever that virus was coding itself, and replaced it with the healthy copy of the gene that we would like to deliver to the body. 27:52 Mm-hmm. So basically, what you're doing is that you're using the shell of the virus, like what we call- Sure... the capsid of the virus, the surface of it- Okay... as a FedEx truck to, [laughs] 28:04 to deliver the genes to the tissues that we want. 28:08 We basically load it up with the healthy copy of the gene, inject it into blood, and then we need to give it the exact address of, okay, you need to take this gene to the muscle tissue. 28:19 You need to take this gene to the heart. Right. You need to take this gene to the lung. And I think the most important bottleneck during the last two decades was giving the right address to this FedEx machine. 28:31 Wonder if you can describe that a little bit because there was a hurdle for quite a while, right? Where the side effects were, I mean, to put it lightly, detrimental. Exactly. 28:38 Could you, could you talk about that so, again, people can understand how difficult it's been to get to where we are? Yes, definitely. 28:44 The viruses that are norm- normally present in nature, we call them naturally occurring viruses, so these are the ones that have evolved in nature for many, many years. Mm-hmm. 28:56 And those viruses, when they enter the bloodstream, different animal models, including humans, they mainly get into the liver tissue, and part of the reason is that, you know, liver is responsible for removing whatever foreign that gets into your body, but at the same time, they have been evolved in nature to interact with liver cells or hepatocytes more. 29:18 And the very first generation of gene therapies just use these naturally occurring capsids. Actually- Mm-hmm... almost every gene therapy that's in clinical trials right now are using naturally occurring capsids. 29:32 And for that specific reason, most of these drugs, after injection of the blood, into the bloodstream, almost like 90% of them- Mm-hmm... will end up in the liver. 29:43 And then there would be about like 10% that goes into like other tissues, but that definitely overloads the liver. That would- Okay... introduce an extremely high dose of virus, right? 29:55 That, that's like a massive viral infection in the liver. Mm-hmm. And that has, unfortunately, resulted in a few instances of serious adverse effects. 30:06 In one specific trial for pediatric disease, uh, named X-linked myotubular myopathy, there have been four deaths after injection of the gene therapy out of 17 patients or 18 patients that got injected, which, which has been-Really tragic and dramatic. 30:23 And the main reason for that has been associated with liver toxicity because- Okay... because ninety percent of it ends up in the liver, then you need to inject- Sure... 30:31 an extremely high amount, so the remaining ten percent is still enough to give you therapeutic efficacy. But then when you get ninety percent of it in the liver, it causes liver toxicity in these kids. 30:43 The bottleneck, the major hurdle at this point for gene therapy is not therapeutic efficacy. We know that if you get eno- enough of these drugs into the right tissue, it's gonna fix the problem. 30:56 The problem is- We know that works... how do you do it safely? How do you do it- Right... in a way that you're not gonna have serious adverse effects? 31:03 And a lot of this is associated with the dose of the virus that we inject. Like, the higher the dose of the virus, the higher the chances of toxicity. Mm. And there are... other than liver toxicity, there are 31:16 some other aspects of the immune system, specifically they're called complement activation. 31:21 It gets technical, but you, you basically activate the immune system in ways that could result not only in liver toxicity, but also in kidney injury and other associated effects. 31:33 So the main point that FDA is really concerned about at this point, a lot of gene therapy companies are struggling with, is how can we lower the dose? How can we make gene therapy safer? 31:48 And one way to do this is obviously to give a better address to these viruses that we use for delivering genes, right? To tell them, "Okay, you, you should not go into the liver. 32:01 You should go to the tissue that we would like you to." But how do you do that? 'Cause that seems obvious, so why wouldn't we have done that before? 32:08 Is that technological or- It's mainly technological advances and also being able to do high throughput experiments, right? Because sequencing is getting cheaper and cheaper every day. Sure. 32:23 And the ability for us to make many, many, many-- to synthesize DNA fragments that we can use for our experiments at a much higher pace for cheaper, then we can actually do thousands and thousands of experiments in one experiment because we can- Okay... 32:39 like pool all of them together. Sure. So what could have taken maybe like a couple years to do, it could take a couple of months. 32:46 And it also is the fact that because now we're at a stage that gene therapy has a lot of promise- Mm-hmm... a lot of people from different fields of science have taken interest into it. Okay. 32:59 And that adds a lot of value because they bring in new expertise, right? People- Sure... who make high throughput libraries know they're interested in gene therapy, and they bring their own set of skill set to this. 33:10 And then when you put all of these sets together, science advances much faster. Do you guys need podcasters? [laughs] Because I know a guy. [laughs] Yeah, that would certainly help. [laughs] Sure, sure, sure. 33:23 Interesting. Okay. So it's a combination of technological because, I mean, we really just sequenced the genome, right? It was really not that long ago, and the cost structure for doing that has come down. 33:34 The ability to do, like you said, these immense, uh, libraries to do multiple experiences, uh, at a time, and then bringing in interdisciplinary folks who can ask better questions and bring both more and different perspectives. 33:46 We see this all the time, right? It's not an insult to some specific field. It's just that more varied thought tends to expand the options of, of how to move forward. 'Cause like you said, you know it works. 33:56 It's just the mechanism for getting there wasn't doing it, and you didn't know how to say like, "Drop the package at this house." Exactly. Which Amazon knows how to do at my house very well. 34:05 [laughs] I think about the analogy of... 34:08 and please again, correct me if I'm wrong 'cause that's my entire life, and I actually kind of enjoy it, but I think about the analogy of, again, going back to those mRNA vaccines, which among the most incredible human achievements in both their efficacy and the timeliness, obviously, and another thing that really only possible in sort of twenty twenty, twenty twenty-one with how far we've come. 34:30 And so for many folks, they're very new and they're exotic, which is, uh, part of the success and part of the issues with the understanding around them. 34:37 But in reality, they've been in, in development for decades, and we know they could work. But, you know, I think about Dr. 34:42 Katalin Kariko and, and she cracked one of those hurdles, which is making sure the body doesn't freak out with inflammation when we use them, and that unlocked our ability to actually use them. 34:52 Is that analogous to your contribution to the field, to saying like, "Oh, now we know how to direct this to a specific address?" Or am I completely off base, which is entirely possible? [laughs] No, no, no. 35:02 No, you're not, you're not off at all. 35:04 For mRNA vaccines, there have been years and years of different, you know, groups working on showing how to make modified RNA, how to basically optimize it in a way that it's safe in delivering into cells and into body in general. 35:19 Mm. Can we use that for gene therapy? And like, I think through those experiences, folks actually understood that mRNAs could be really good tools for actually inducing immune response- Mm... 35:32 for producing a protein for a very short amount of time, that immune system sees it, and then you can induce massive immune response. 35:40 I think if the pandemic did not happen, there was a chance that we could not unlock the potential of mRNAs for generating vaccines because, you know- Sure... 35:52 you need a very large number of people to, to these type of clinical trials. But what we see right now is not that, okay, we suddenly come up with the idea of using mRNAs to make vaccines. 36:02 It was like twenty years of work that went into it, and it's the exact same thing for our case. Like, we learned so much from the work of, uh, people who have studied fundamentals of AAV biology, right? Mm-hmm. 36:14 How the capsid is formed. What is the crystal structure of the capsid? How can we modify it in a way that can, we can still make virus? Because we are changing the surface of the capsid. 36:25 We are evolving these capsids in a way that we want to give it new instructions. How would we able to do this while not perturbing the basic biology of the virus, right? Mm-hmm. 36:38 So what we did was-Learning from all these basic aspects of biology and bring in new sets of technologies into it. 36:49 Looking at it from a different perspective that what could be the reason that previous attempts for making this happen have not been as successful? How can we change? And that took us a few years too, right? 37:01 I think it would took about like, uh, two to four years to come up with this technology that we can actually implement to specifically find those viruses or engineer those viruses to get into the muscle tissue, but, uh, having the knowledge from the research that has been done previously was definitely essential. 37:20 So it's interesting, Kamyar, 'cause again, they're these two situations, the work you're doing and for instance, these COVID-19 mRNA vaccines, right? 37:29 Like you said, they both stand on decades of research and a lot of left turns, and incredible well-intended folks working their entire t- careers to make these things work, and on the o- one hand going, "I know it works. 37:39 I don't know how to get us there," right? Safely at least, you know, without hurting people, and I always think about chemotherapy and things like th- these blunt instruments we have, the best answers we have. 37:48 But you made a point that we might not be where we are with these mRNA vaccines now going, "Holy shit, what else can these things do?" If the N of people who needed them wasn't every person on the planet suddenly. Yeah. 38:00 Yeah. 38:00 But rare muscle diseases haven't had that moment, thankfully, but you've still made quite the jump, and I think about, and I, I read a little bit about at one point, you were finally able after years of going, "What the hell is going on with my dad?" 38:17 He didn't induce this in any way knowingly, and the environment around him, again, unlike New Delhi or, or LA how it used to be, whatever it might be, what's going on? And much less like, "How can I treat him?" 38:29 But at some point on a day, you were actually finally able to sequence his genome. What happened that day? What surprised you? What scared you? And how has that contributed to where you are now? 38:42 Over the years, that has always been a question in my head, right? We know that it's a progressive muscle condition. 38:51 There was a lot of information out there that this could be associated with some sort of muscular dystrophy, but there was no formal diagnosis, and whenever I talked with my dad, I was like, "Okay, 39:04 I think we need to get to the bottom of this. We need to see what exactly this is. We need... We know that it's a degenerative muscle condition. We don't know what exactly it is." 39:12 And his answer mainly was, "Well, why would it matter if there's no cure?" It's like, well, it does matter because then if there is a potential treatment, then you could potentially get enrolled in clinical trials. 39:24 And I am personally in the camp of people who would like to have more than less information. The other part of it was, I think, also selfish that I wanted to see if I have it or not, or if, you know- Of course... 39:37 we did perform sequencing. 39:39 We had started with a small subset of genes, and we did not find any mutation in those genes, like most of the genes that are involved in genetic muscle disease, and that was the point that I really understood where we stand on genetic diagnosis because a lot of folks do have-- You know, they're in the same boat as my dad. 39:58 Like they have symptoms, but they just can't figure out what it is. Sure. 40:02 They keep going to different doctors that we can sequence the whole genome now, but how can you pinpoint that one specific nucleotide change that gets associated with your disease, right? 40:13 There could be multiple different like changes in different genes that may or may not have an effect on, uh, the health of the human body, but pinpointing it to that specific disease is, is still a challenge. 40:26 Like a lot of people deal with that. So we did sequence basically every single protein coding gene in his body, and still we did not find anything. And I was like, "Okay, this does not make any sense." 40:37 Like th- there is- Sure... like what is going on here? So I started talking to people who, uh, specifically at Harvard, who are more working on diagnosing genetic diseases with a focus on genetic muscle diseases. 40:50 I have a very good friend, Monk Lake, who's a, an assistant professor at Yale right now, and he mentioned that, "Well, have you looked at repetitive areas in the genome?" 41:00 Like there are some parts of the genome that you have like multiple repeats of the same sequence, and with the current technologies that we sequence the genome, you can't really find out if there's something wrong with those repetitive regions. 41:14 Sorry, is repetition usually instructive of something going wrong, or is that just something that's normal? No, it's, it's normal. It's normally present- Okay. Okay... in the, in the human genome. 41:23 So he said check out the repetitions. Yeah. So basically if, if there is a change in those repetitive regions, we can't really pick it up by doing sequencing because like it- Ah... 41:31 it gets complicated, but because of the way the sequencing is done. Sure. And they said, well, there are other ways that you can change these areas, but then you need to like do specific experiments. 41:42 And he introduced me to Peter Jones at University of Nevada, who actually does a lot of these type of analysis for FSHD particularly. 41:52 When he analyzed the DNA, uh, for my father's sample, he called me up and said, "Yeah, it's FSHD type one." And his second question was, "Do you know what that means?" [laughs] And I said, "Yes." 42:07 He said, "Yeah, you have fifty percent of chance of having this disease. Do you want to get tested?" And my immediate answer was, "Yes, I want to get tested." 'Cause you want more information. Yeah. 42:18 That, that's how it, uh, happened. I had to communicate that to my father that we finally have an answer to what your condition is. The, the journey of diagnosis ended at that point. 42:29 [laughs] How long between your friend, new friend, Peter, uh, who finally was able to diagnose your father, when he said what the disease was, were you aware of it or was it entirely new to you? 42:42 No, I, I knew what FSHD is. Yeah. Okay. Okay. That was something that we thought about for sure as a potential. 42:48 How long in between him-Helping you understand what it was to you discovering the answer to whether you would get it or not. Hours, days, weeks? I think two or three weeks. So I had to send 43:00 a sample to him, and then for me to analyze it. And, uh, he gave me a call, and I completely remember that day. He told me that, "You are the luckiest guy among the unluckiest." I was like, "What does that even mean?" 43:14 He said, "Well, you, you inherited that gene from your father." But what happened was that, again, this, this gets really technical, but when 43:26 the germ cells are being generated, there is this whole phenomenon of recombination that happens. Mm. 43:32 That the very last part of that toxic gene that they inherited was recombined with like a, a different chromosome that didn't have that part. And he said that this doesn't happen often. 43:47 [chuckles] I have not seen it before, but you got the gene, you just got a truncated version of that gene, and that's why you're not sick. [laughs] And I was like, "What are the chances," right? 43:59 [laughs] I mean, quite literally, like, I can't even fathom what the chances might be for, like you said, the... you're the luckiest of the unlucky. 44:05 If this is an incredibly rare thing that it took, uh, decades to, to diagnose in the first place, and experts who had no idea, and, and the first test showed nothing, and then you just happen to not get it, I mean, is, is incredible. 44:19 So what did that mean for your father's condition and treatment? Were there any answers? Are there any answers for him today? I think what really changed was the fact that I knew where to focus, right? 44:33 Before that, my main focus was figuring out, like, developing a specific technologies that help the genetic muscle disease community as a whole. 44:45 And I think the advancement that we made by developing my AAV, it's going to change the whole field. 44:51 It's going to affect every single genetic muscle disease, the treatment, and I would like to focus on developing these type of technologies going forward, developing better regulatory elements that express the gene in the muscle or addressing other major challenges. 45:08 But at the same time, I know that I really wanna figure out how to treat the physician. So I want to put a lot of focus, a lot of effort into 45:18 first understanding the disease better and second, developing effective treatments for people who have this type of disease, because I have seen firsthand how they can... how it can affect their life. 45:30 And now you have moved on to doing that more specifically. You've left the Harvard-MIT combo, uh, the Broad, to head out to sunny San Diego. So what does that mean? 45:42 When were you like, "This is the time to start actually applying this"? 45:46 I think when we developed the technology, it was quite striking to see that, you know, how much more effective we are compared to these naturally occurring capsules. 45:55 We can go with doses ten to a hundred times lower compared to what people are using in the clinic, and that could definitely solve the issue for Duxody, at least in the, in the preclinical studies. 46:06 We may see unforeseen incidents happening in the clinic, and we need to be prepared for that, but there is a very good chance. 46:15 I think the time point that made me make that decision was when we saw the reaction from the community, when we saw how muscle disease researchers, gene therapy researchers are reacting to our finding, right? 46:31 It was not ignored. It was something that people appreciated. People said that, "Okay, this is it." Like, this has a really good chance of solving this problem. 46:40 And I personally was in the camp that I wanted to go into academia, and I wanted to start a research lab, and I wanted to like, you know, do academic research. 46:48 But when that happened, it occurred to me, this is your chance. If you want to really actually do it, you have to go all in. 46:56 You have to make sure that you put all your effort and energy in making sure that this goes right, this is done properly, and, and actually get some medicines to patients. 47:07 So I think that wa- that was the point that gave me the confidence that I need to make this move. It was getting out of my comfort zone. 47:14 It was doing something that I had not done before, but I think that was the right decision. I'm really happy that I made that change. We have started a company now on the same technology. We are building a team. 47:27 We're moving technology forward towards clinic as fast as possible. It's really fun. 47:31 It's a fun ride to see it go through and then, you know, think about the questions of what would happen when we inject our first patient. That is quite exciting. 47:41 [chuckles] Before I make another analogy to Michael Owen signing with Real Madrid later in his career to test new waters, I can understand to some folks in the community how this would seem like a natural evolution of both your career and the field. 47:53 But at the same time, we talk a lot here about, uh, things that are, again, if mRNA was like, "Hey, guess what?" It's, it's everybody. 48:00 I know you've got a couple pharmaceutical companies, you know, making a lot of money off that, and they've made huge contributions, of course. And they made those contributions with a lot of federal backing. 48:09 But there's a lot of areas, rare cancers, childhood cancers, uh, diseases like this one, even though there's a, a wealth of diseases and genetic diseases and, and muscle dystrophy diseases, you know, relative to something like heart disease, right? 48:25 They're much smaller, and they don't get the funding, and it's... 48:28 America has, for some insane reason, made it very difficult to get technologies out of the lab and commercialized because often there's just not enough profit behind that. 48:37 So what you're doing is actually pretty fundamental and pretty important because there's just not a lot of that in fields like this where we see, oh, shit, we might be able to actually do this and make a huge difference pretty quickly to, again, a relatively smaller group of folks, but a group of folks who are suffering nonetheless, and, like, and we just sequenced this thing. 48:55 We've just made these strides. You've just been able to look at it more deeply and see, like, yes, we can see the whole genome, but where is the broken part, or where is the repetitive part and the broken part? 49:04 This is actuallyQuite a big moment for the field. It is. It is indeed. Yeah, I think it changes the game a little bit because we know that there is definitely path forward for having safe and effective products. 49:17 It's easier to justify dedicating funding, right? Mm-hmm. 49:20 It's easier to go out there and say that, "Hey, like, look, we have shown that this is possible in these animal models at a very low dose, and we have a very good chance of making it happen in humans." 49:34 So I, I hope at least that it makes it easier for allocating more resources for researching gene therapy for chanting disorders. 49:43 I mean, you'd think if you finished top five among the million plus students taking these practice tests and these tests and flip-flapping first and second, that this is where you would end up as, as someone who, who transparently stands on the s-shoulder of so many decades of research while you were growing up and, and watching your dad deal with this progressive disease. 50:02 But at the same time, it's gotta feel pretty incredible to feel like now I can actually make this impact to the people who are, who are suffering with it. 50:09 People who, like you said, like your father, didn't do anything to induce this voluntarily in, in any way. Yeah. You're, you're, you're very kind to me. But yes, it does feel incredible. 50:20 [laughs] It, it is what I have worked for many, many years, and the fact that we see there is a path forward now. 50:28 Like, the fact that I can actually now think about we're gonna be injecting patients sometime soon, it gives me chills. It gives me a lot of excitement. 50:38 And yeah, I keep thinking about it, that we are actually gonna see the impact of the drugs that we're developing in patients' lives. There could be people who may not need to sit on wheelchairs anymore. 50:50 There, there could be kids who can live a normal life, play with their classmates and with their friends instead of being on a ventilator. So that is really incredible. 51:02 That what makes me get out of the bed, bed every day. It's incredible. I mean, the, these are the stories we hope to tell here to both again, shine a light on your work, but also to inspire and encourage long... 51:14 other folks who are feeling adrift in some ways or feeling challenged or feeling intimately touched, uh, again, by something like this, who are going, "What can I do?" 51:25 And you've chased a pretty direct line trying to solve this for yourself, for your, for your father, and your, and your family and, and all the other folks, again, who are, who are dealing with this. Pretty incredible. 51:36 The, the point that I try to communicate with folks quite often is that when you have unfortunate events happening in your life, you know, there are a few ways that it can go. 51:52 You can really feel bad and say that, "Well, life is unfair, and I can't do anything about it," and give up. Mm-hmm. Or you can actually think about it, "Okay, this is a challenge." You know? 52:05 "This can give my life a mission. This can make me understand that what do I want to do in my life?" And if you go the second way, and if you find 52:18 a specific way that you can use what you're good at, your talent, and what you're passionate about, and marry it with the mission of your life, then that's going to be key. 52:28 Like, I think all the, all the very successful people that I've seen when I was in Boston or, you know, the, the people who I have encountered in my network, they're people who what they're really passionate about in life fit what they're really good at. 52:44 And identifying those two are key. I think finding out w-where is your talent, because everybody's good at something, right? I'm, I'm terrible in music. Like, I'm, I'm not good in art. But I'm a good scientist. 52:58 I know how to solve puzzles. I know to, like, how to troubleshoot experiments. And identifying that talent, I think, is as important as what do I want to do with my life? 53:10 And then if you can put them together, then that's going to be the recipe for success. I think that could help people live a happier life, to basically give it a positive spin. 53:20 This is what my PhD advisor, Amy Wagers, always told me, that there's going to be days that you would feel really down, that you have, you have big, big failures for experiments that you've worked for so long. 53:33 But always think about, "How can I put a positive spin on this? How can I actually use this to start a new challenge, to basically learn from it and leverage it to do something good and meaningful?" 53:46 Having that mindset is not easy, but it makes life much easier. [chuckles] I love that. I mean, again, if anything encapsulates what we're trying to do here, it's that. 53:54 It's help people answer that question and point them in that direction 'cause it, frankly, you know, our, our challenges and our opportunities are, are so many and so varied and often so globally consequential or intimately consequential. 54:08 It frankly doesn't matter what you're good at because we need all of it, and every bit of it can contribute, whether you're an artist or you're good at music, or you're a scientist who can solve puzzles, or me, I can plug in a microphone and convince people to come talk to me for a little while. 54:23 [laughs] It does matter, and, and hopefully it'll move the needle for someone somewhere, if not many of us, especially those of us, again, who are born, uh, with something that is nearly undetectable for, for three decades, but they didn't instigate in any way, but they deserve to, to benefit from whatever science we can achieve along the way. 54:41 So I appreciate all of your efforts and your time, certainly. Thank you. Thanks. I'm gonna ask you one last question before we, uh, get you out of here. Total pivot, doctor, as if you had time for anything like this. 54:52 But what is a book you've read in the past year or so that's opened your mind to maybe a topic you hadn't considered before or it's actually changed your thinking in some way? 55:01 And we've got a whole list of recommendations we throw up on Bookshop for everybody. I would be fascinated to hear. I think there are a couple of books that comes to my mind.Okay. 55:11 One of them is Never Split the Difference by Chris Voss. Okay. And the other one is obviously Becoming by Michelle Obama. I mean- [laughs] Do you know she read the audiobook? So I set it up. 55:24 I think my wife understood, but also, like, chagrined, was I would make it so Michelle Obama was the first thing I heard in the morning, and then the last thing I heard at night. [laughs] And it was great. 55:32 It was a really good period for me. Yeah. Tell me about Never Split the Difference briefly. Never Split the Difference is a book that talks about how to negotiate [laughs] Mm. 55:44 And basically teaches you that everyday life is, is a negotiation. It's just how to think about interacting with people. 55:53 Like, what kind of perspective you have when you talk to other individuals, and how to look at it from their perspective, right? How to answer questions. 56:02 If you want to ask for something, how can you ask it in a way that considers other people's... takes other people's emotions into consideration, and basically enables you to come to agreements with people. 56:19 The way, the tone that you have your conversations, have your requests, or how do you answer these questions. It was written by... this was, was a FBI negotiator, uh- Mm... 56:32 for hostages internationally, and it's basically from years of his experience. That has made a big impact in how I communicate with people, [laughs] Sure... and how I negotiate. 56:43 But yeah, Becoming, obviously, was also another book that, that I learned everything is possible if you do it the right way, you really want to do it, and you have a supportive structure in front of you. 56:57 Like, the whole story of Obama's coming from, you know, the South Side of Chicago to the White House, and how it happens, you know, being ordinary people, not privileged individuals who worked their way up, that, that inspires me, obviously. 57:11 I love it. [laughs] I'm gonna reread Becoming. I'm going to sit down at night and read Never Split the Difference to my six-year-old, and we're gonna find a way forward, and I'm very excited about it. There you go. 57:21 [laughs] So thank you. Negotiating with terrorists. [laughs] Sharif, I cannot thank you enough for your time today, and your efforts, and, and all of your work. 57:29 I'm so excited to see it come to fruition, though I imagine there will be more obstacles and failures along the way. But, um, I imagine that'll keep you pushing in that direction. 57:37 Didn't get a lot of time to talk about Michael Owen and Liverpool, which I'm sure everybody's very upset about. [laughs] I will come visit you, and we'll have a whole separate conversation about that. 57:47 I'm sure we could go on- Definitely. [laughs]... forever. The man who placed top 10 in Iran, and the youngest player to win the, to win the Golden Boot. [laughs] The analogies are many. Wow. Sharif, thank you so much. 57:57 I really appreciate it. Thank you. I, yeah, it was a lot of fun. Thanks so much. And definitely let me know when you come to San Diego. [laughs] Absolutely. 58:05 [upbeat music] Thanks to our incredible guest today, and thanks to all of you for tuning in. 58:11 We hope this episode has made your commute, or awesome workout, or dishwashing, or fucking dog-walking late at night that much more pleasant. 58:20 As a reminder, please subscribe to our free email newsletter at importantnotimportant.com. It is all the news most vital to our survival as a species. And you can follow us all over the internet. 58:31 You can find us on Twitter at importantnotimp. Just so weird. Also on Facebook and Instagram at importantnotimportant. Pinterest and Tumblr, the same thing. So check us out, follow us, share us, like us. 58:44 You know the deal. And please subscribe to our show wherever you listen to things like this. And if you're really fucking awesome, rate us on Apple Podcasts. Keep the lights on. Thanks. Please. 58:53 [laughs] And you can find the show notes from today right in your little podcast player and at our website, importantnotimportant.com. 59:00 Thanks to the very awesome Tim Blaine for our jammin' music, to all of you for listening, and finally, most importantly, to our moms for making us. Have a great day. Thanks, guys. 59:14 [outtro music] [upbeat music] That's it for this week's conversation. 59:26 For more conversations, scroll back in the feed or visit podcast.importantnotimportant.com to search by name, topic, whatever. Thanks for sharing, thanks for leaving a review, and thanks for giving a shit. 59:40 [outtro music]